Annexon Valuation Multiples

Annexon Overview

About Annexon

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Founded

2011

HQ

Employees

100

Website

annexonbio.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

EBITDA: ($215M)

EV

$773M

Valuation Multiples

Multiples.vc

Start free trial

Annexon Financials

Annexon reported last 12-month revenue of — and negative EBITDA of ($215M).

In the same LTM period, Annexon generated — in gross profit, ($215M) in EBITDA losses, and had net loss of ($208M).

Annexon P&L

In the most recent fiscal year, Annexon reported revenue of — and EBITDA of ($214M).

Annexon expects next 12-month revenue of XXX and NTM EBITDA of XXX

Annexon Stock Performance

Annexon has current market cap of $985M, and enterprise value of $773M.

Annexon's stock price is $6.14.

Annexon Valuation Multiples

Annexon trades at (3.6x) EV/EBITDA.

Annexon Financial Valuation Multiples

As of April 10, 2026, Annexon has market cap of $985M and EV of $773M.

Equity research analysts estimate Annexon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Annexon has a P/E ratio of (4.7x).

Annexon Margins & Growth Rates

Annexon's revenue in the last fiscal year grew by —.

Annexon's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.2M for the same period.

Annexon Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Annexon M&A Activity

Annexon acquired XXX companies to date.

Last acquisition by Annexon was on XXXXXXXX, XXXXX. Annexon acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Annexon Investment Activity

Annexon invested in XXX companies to date.

Annexon made its latest investment on XXXXXXXX, XXXXX. Annexon invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).